A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV

Fidec

Status and phase: Completed; Phase 3

Conditions: Poliomyelitis

Treatments: Biological: f-IPV; Biological: IPV

Study type: Interventional

Funder types: Other

Identifiers

NCT03239496

IPV004

Details and patient eligibility

About

The study will assess and compare the immune response to full-dose inactivated polio vaccines (IPV) via intramuscular (IM) administration and of the fractional dose of inactivated poliovirus vaccine (f-IPV) via intradermal (ID) administration, in different schedule combinations in the Expanded Program on Immunization (EPI) primary series.

Full description

This study prioritizes comparisons involving two-dose regimens recently recommended by the World Health Organization (WHO) Strategic Advisory Group of Experts on immunization (SAGE) and Pan American Health Organization (PAHO) in response to global IPV supply shortages 21. Furthermore, the study will provide data on the comparative humoral immunogenicity of various schedules to inform polio immunization policy for the post-eradication era.

The study population will include infants in Dominican Republic and Panama. Absence of wild and circulating vaccine derived polioviruses along with the lack of regular Supplementary Immunization Activities (SIAs) in the Latin America region provide an ideal epidemiologic setting to study polio vaccine immunogenicity.

Infants will receive two or three doses of full-dose IPV IM or f-IPV ID, in two schedules (10, 14 and 36 weeks and 14 and 36 weeks). Immunological and safety assessments will be made after one dose, two doses and three doses.

A total of 773 infants will be enrolled and distributed into 4 groups, according to a randomization scheme. During the study period, infants will be administered other concomitant vaccines according to the national schedules of the participating countries, but the effect, if any, of the concomitant administration on IPV immunogenicity will not be assessed.

Optimum immunogenicity expected from the dose(s) of IPV in the post-eradication era will have to be balanced with the cost and supply constraints of IPV. This study will be critical to determine how many doses of IPV and which schedule are optimal for the post-eradication era after the global cessation of Oral Polio Vaccine (OPV) use.

Enrollment: 773 patients

Sex: All

Ages: 5 to 7 weeks old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Infants of 6 weeks of age (-7 to + 7 days) on date of enrollment.
2. Healthy, as assessed from medical history and physical examination by a study physician,
3. Written informed consent obtained from parents or legal representatives who have been properly informed about the study and are able to comply with planned study procedures.

Exclusion criteria

1. Vaccinated with any poliovirus vaccine prior to inclusion,
2. A household contact with OPV vaccination history in the past 4 weeks,
3. HIV infection or pharmacologic immunosuppression,
4. Known allergy to any component of the study vaccines (phenoxyethanol, formaldehyde),
5. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular and intradermal injections,
6. Acute severe febrile illness on day of vaccination deemed by the Investigator(s) to be a contraindication for vaccination,
7. Not suitable for inclusion or is unlikely to comply with the protocol in the opinion of the investigator(s).

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

773 participants in 4 patient groups

Group A

Experimental group

Description:

3 doses IPV IM at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 14, 18 \& 40 weeks.

Treatment:

Biological: IPV

Group B

Experimental group

Description:

2 doses IPV IM at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.

Treatment:

Biological: IPV

Group C

Experimental group

Description:

3 doses f-IPV ID at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 14, 18 \& 40 weeks.

Treatment:

Biological: f-IPV

Group D

Experimental group

Description:

2 doses f-IPV ID at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.

Treatment:

Biological: f-IPV